GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
COVIDIEN LTD. COMMON SHARES (COV) [hlAlert]

Rating:
Buy COV
up 140.98 %

COVIDIEN LTD. COMMON SHARES (COV) rated Buy with price target $77 by Deutsche Bank

Posted on: Monday,  Jan 27, 2014  2:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy COVIDIEN LTD. COMMON SHARES (NYSE: COV) on 01/27/2014. Previously Deutsche Bank rated Buy COVIDIEN LTD. COMMON SHARES (NYSE: COV)
on 11/10/2010., when the stock price was $44.28. Since then, COVIDIEN LTD. COMMON SHARES has gained 140.99% as of 01/26/2016's recent price of $106.71.
If you would have followed the previous Deutsche Bank's recommendation on COV, you would have gained 140.98% of your investment in 1903 days.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2014 2:25 PM Buy
None
68.03 77.00
as of 10/17/2014
1 Week down  -11.54 %
1 Month down  -9.81 %
3 Months down  -5.57 %
1 YTD up  20.70 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/1/2013 2:25 PM Buy
None
57.75 68.00
4/12/2013 3:25 PM Buy
None
67.81 74.00
1/4/2013 2:25 PM Buy
None
58.81 70.00
2/2/2011 8:25 AM Buy
None
48.98 59.00
1/18/2011 1:25 PM Buy
None
47.17 56.00
11/10/2010 1:25 PM Buy
None
44.28 52.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy